Abstract: A formulation comprising an ingestible carrier and an isolated strain of Bifidobacterium longum.

Abstract: A formulation comprising an ingestible carrier and an isolated strain of Bifidobacterium longum.

Abstract: The current invention provides use of a CLA-producing bacterium for the in vivo conversion in the gut of polyunsaturated fatty acids to CLA. The CLA-producing bacterium is selected from one or more of the group consisting of propionibacteria, lactobacilli, lactococci and streptococci, and bifidobacteria.

Abstract: A formulation comprising an ingestible carrier and an isolated strain of Bifidobacterium longum.

Abstract: Probiotic Bifidobacterium strain AH1714 is significantly immunomodulatory following oral consumption. The strain is useful as an immunomodulatory biotherapeutic agent.

Abstract: Probiotic Bifidobacterium strain AH1714 is significantly immunomodulatory following oral consumption. The strain is useful as an immunomodulatory biotherapeutic agent.

Abstract: Probiotic Bifidobacterium strain AH1714 is significantly immunomodulatory following oral consumption. The strain is useful as an immunomodulatory biotherapeutic agent.

Abstract: Bifidobacterium strain AH121A is significantly immunomodulatory following oral consumption. The strain is useful as an immunomodulatory biotherapeutic agent.

Abstract: According to the invention there is provided a strain of lactic acid bacteria of the species Bifidobacteria pseudolongum obtainable by isolation from resected and washed canine gastrointestinal tract having a probiotic activity in animals. Methods of use and compositions comprising the Bifidobacteria pseudolongum of the present invention are also provided.

Abstract: According to the present invention there are provided methods of use in companion animals of probiotic bacteria of the genus Bifidobacteria.

Abstract: According to the invention there is provided a strain of lactic acid bacteria of the species Bifidobacteria globosum obtainable by isolation from resected and washed canine gastrointestinal tract having a probiotic activity in animals. Methods of use and compositions comprising the Bifidobacteria globosum of the present invention are also provided.

Abstract: According to the invention there is provided a strain of lactic acid bacteria of the species Bifidobacterium globosum obtainable by isolation from resected and washed canine gastrointestinal tract having a probiotic activity in animals. Methods of use and compositions comprising the Bifidobacterium globosum of the present invention are also provided.

Abstract: According to the present invention there are provided methods of use in companion animals of probiotic bacteria of the genus Lactobacilli.

Abstract: The current invention provides use of a CLA-producing bacterium for the in vivo conversion in the gut of polyunsaturated fatty acids to CLA. The CLA-producing bacterium is selected from one or more of the group consisting of propionibacteria, lactobacilli, lactococci and streptococci, and bifidobacteria.

Abstract: Disclosed are compositions comprising an inner core and at least two surrounding layers. The compositions are suitable for use in humans and other mammals, particularly wherein a component of the inner core is susceptible to moisture. The compositions comprise an inner core comprising one or more components; an inner layer which surrounds the inner core, wherein the inner layer is selected from continuous coatings insoluble at a pH of about 3 or less, continuous coatings having a coating weight of from about 3 mg/cm2, and combinations thereof; and an outer layer which surrounds the inner layer, wherein the outer layer is hydrophobic.

Abstract: The current invention provides use of a CLA-producing bacterium for the in vivo conversion in the gut of polyunsaturated fatty acids to CLA. The CLA-producing bacterium is selected from one or more of the group consisting of propionibacteria, lactobacilli, lactococci and streptococci, and bifidobacteria.

Abstract: Disclosed herein are methods for treating a respiratory condition in a mammal, such as a human. The methods employ use of a composition comprising a Bifidobacterium probiotic.

Abstract: Novel methods of determining efficacy of a treatment of inflammatory diseases of the bowel in mammals are provided. The methods are of use in screening and determining the efficacy of treatments of inflammatory diseases of the bowel, and for determining the efficacy response of individual sufferers of inflammatory diseases of the bowel to a given regime. Kits for carrying out the method are also provided.

Abstract: Novel methods of determining efficacy of a treatment of inflammatory diseases of the bowel in mammals are provided. The methods are of use in screening and determining the efficacy of treatments of inflammatory diseases of the bowel, and for determining the efficacy response of individual sufferers of inflammatory diseases of the bowel to a given regime. Kits for carrying out the method are also provided.